# Nicholas Naclerio

> Nicholas Naclerio is a Series B investor at Illumina Ventures backing Biotechnology and Medical. See 15 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Illumina Ventures](https://shizune.co/investors/profile/illumina-ventures)
- Location: San Francisco, United States
- Total investments: 15
- Last investment: Feb 2024
- Lead investor: 40%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/nick-naclerio-68235b8/
- Facebook: https://www.facebook.com/nick.naclerio.9

Nicholas Naclerio is a Series B investor at Illumina Ventures in San Francisco focused on Biotechnology and Medical. Nicholas J. Naclerio is based out of San Francisco, California, and is the Founding Partner of Illumina. Nicholas previously worked at Quanterix as a Co-founder and Executive Chairman. Nicholas J. Naclerio attended the University of Maryland.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 47% |
| Medical | 5 | 33% |
| Health Care | 5 | 33% |
| Life Science | 2 | 13% |
| mHealth | 1 | 7% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 27% |
| Series C | 4 | 27% |
| Series A | 3 | 20% |
| Seed | 1 | 7% |
| Series D | 1 | 7% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 33% |
| France | 2 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Stilla Technologies | Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System.Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all LifeSciences areas: research, therapeutics, and all the “omics”. | $26.5M | Series C | Feb 22, 2024 |  |
| Tagomics | Tagomics transform disease diagnosis through comprehensive multitopic profiling. | $8.5M | Seed | Feb 21, 2024 |  |
| Pattern Bioscience | Pattern Bioscience is a privately held in vitro diagnostics company founded in 2016 to help combat the problem of antibiotic resistance. Pattern is developing a next-generation clinical microbiology platform based on its patented phenotypic single-cell technology that can rapidly identify pathogens and determine their antibiotic response withoutthe need for traditional time-consuming culture steps. Pattern’s Digital CultureTM technology relies on functional endpoints that encompass all possible resistance mechanisms, resulting in a more comprehensive and reliable diagnosis compared to rapid genotypic tests. The platform will deliver more reliable diagnoses days faster than the current standard of care. | $28.7M | Series C | Apr 27, 2023 |  |
| Stilla Technologies | Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System.Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all LifeSciences areas: research, therapeutics, and all the “omics”. | $34.9M | Debt Financing | Nov 23, 2021 |  |
| DNA Script | DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results. | $165M | Series C | Oct 26, 2021 |  |
| Alamar Biosciences | Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California. | $80M | Series B | Sep 08, 2021 |  |
| LetsGetChecked | LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control overtheir individual health. LetsGetChecked is headquartered in New York, New York, with tests covering general wellness, sexual health, women's health, and men's health, and is available nationwide, as well as in Canada and Europe. | $150M | Series D | Jun 08, 2021 |  |
| DNA Script | DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results. | $50M | Series B | Jul 29, 2020 |  |
| Pattern Bioscience | Pattern Bioscience is a privately held in vitro diagnostics company founded in 2016 to help combat the problem of antibiotic resistance. Pattern is developing a next-generation clinical microbiology platform based on its patented phenotypic single-cell technology that can rapidly identify pathogens and determine their antibiotic response withoutthe need for traditional time-consuming culture steps. Pattern’s Digital CultureTM technology relies on functional endpoints that encompass all possible resistance mechanisms, resulting in a more comprehensive and reliable diagnosis compared to rapid genotypic tests. The platform will deliver more reliable diagnoses days faster than the current standard of care. | $6M | Series B | Jul 14, 2020 |  |
| LetsGetChecked | LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control overtheir individual health. LetsGetChecked is headquartered in New York, New York, with tests covering general wellness, sexual health, women's health, and men's health, and is available nationwide, as well as in Canada and Europe. | $71M | Series C | May 05, 2020 |  |

10 of 15 investments shown.

## Co-investors
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 7 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 5 deals together
- [BNP Paribas Développement](https://shizune.co/investors/profile/bnp-paribas-developpement) — VC Fund, 4 deals together
- [LBO France](https://shizune.co/investors/profile/lbo-france) — VC Fund, 4 deals together
- [Idinvest Partners](https://shizune.co/investors/profile/idinvest-partners) — VC Fund, 3 deals together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 3 deals together

## About Illumina Ventures

VC Fund · Foster City, United States

Illumina Ventures is an independently managed venture fund in a strategic partnership with Illumina. Illumina provides the majority of their capital and access to the expertise and vision of the world's leading genomics solutions provider.They invest primarily in early stage companies, in areas where their expertise and special relationshipwith Illumina can add value. They typically syndicate with other leading institutional and strategic investors.Focus areas include applications of genomics in life science research, healthcare, agriculture and environmental science, public safety and personal wellness.

5 contacts available at Illumina Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Arnaud Autret | Principal | https://shizune.co/investors/profile/arnaud-autret |
| Donal D. Delaney | Chief Financial Officer | https://shizune.co/investors/profile/donal-d-delaney |
| Judy Koh | CFO | https://shizune.co/investors/profile/judy-koh |
| Nicholas Naclerio | Founding Partner | https://shizune.co/investors/profile/nicholas-j-naclerio |
| Suresh Pisharody | Entrepreneur In Residence | https://shizune.co/investors/profile/suresh-pisharody |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Nicholas Naclerio invest in?

Nicholas Naclerio invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series C stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Nicholas Naclerio last invest?

The most recent investment recorded for Nicholas Naclerio closed in Feb 2024. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co